K-5050 KU-55933, >99%

Synonyms : [ATM Kinase Inhibitor]

  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 52
  • 43
  • 37
  • 5,700
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 69
  • 58
  • 49
  • 7,500
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 145
  • 122
  • 104
  • 15,800
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 221
  • 186
  • 158
  • 24,100
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 392
  • 330
  • 281
  • 42,700
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 645
  • 543
  • 463
  • 70,300
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 395.49
  • C21H17NO3S2
  • [587871-26-9]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with warming; soluble in ethanol at 25 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM; buffers, serum, or other additives may increase or decrease the aque. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • KU 55933 is an inhibitor of the oncosuppressor protein ataxia telangiectasia mutated (ATM) kinase. It inhibited ATM with an IC50 of 13 nM and a Ki of 2.2 nM. KU-55933 significantly sensitized Hela cells to the cytotoxic effects of ionizing radiation and chemotherapeutic agents including etoposide, amsacrine, doxorubicin (please see Cat. No. D-4000, Doxorubicin, Hydrochloride Salt), and camptothecin. Hickson, I., et al. "Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM." Cancer Res. 64: 9152-9159 (2004).
  • Blocking ATM/ATR (ATM- and Rad3-related) signaling with KU55933 induced senescent breast, lung, and colon carcinoma cells to undergo cell death via targeting p21CIP1. Crescenzi, E., et al. "Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy." Clin. Cancer Res. 14: 1877-1887 (2008).
  • KU-55933 blocked the phosphorylation of Akt induced by insulin and insulin-like growth factor I, inhibited cancer cell proliferation by inducing G1 cell cycle arrest, and triggered apoptosis during serum starvation in cancer cells. A combination of KU-55933 and rapamycin (please see Cat. No. R-5000, Rapamycin) induced apoptosis and showed better efficacy in inhibiting the growth of cancer cells than each drug alone. Li, Y. and Yang, D.Q. "The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt." Mol. Cancer Ther. 9: 113-125 (2010).
  • KU-55933 suppressed the syncytial apoptosis induced either by wild type HIV-1 or by an HIV-1 mutant lacking integrase activity. Perfettini, J.L., et al. "Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia." PLoS One 3: e2458 (2008).
  • KU-55933 suppressed the replication of both wild-type and drug-resistant HIV-1. Lau, A., et al. "Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase." Nat. Cell Biol. 7: 493-500 (2005).
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.